

Supplemental Digital Content - Appendix: Multivariate hazard ratios for the effect of specific HIV-related time dependent variables on the development of HCC (Model 2)

Variable	Overall cohort HR (95% CI)	cART only HR (95% CI)	Cirrhosis cohort HR (95% CI)
Age at HIV diagnosis	1.09 (1.07-1.11)	1.10 (1.08-1.12)	1.08 (1.05-1.11)
Race/ethnicity (vs. White)			
Black	0.83 (0.61-1.15)	0.67 (0.48-0.93)	0.51 (0.32-0.81)
Hispanic	1.48 (0.98-2.24)	1.20 (0.78-1.85)	0.91 (0.49-1.69)
Cirrhosis (vs. no)			
Yes	4.80 (3.25-7.09)	5.09 (3.40-7.63)	N/A
Ultrasound/ AFP (vs. no)			
Yes	1.16 (0.89-1.52)	1.17 (0.88-1.56)	1.15 (0.75-1.78)
cART era (vs. Pre-cART < 1996)			
Early cART 1996-2001	2.02 (1.42-2.87)	1.45 (0.99-2.11)	2.26 (1.32-3.87)
Late cART 2002-2010	5.07 (2.98-8.63)	2.38 (1.34-4.24)	5.48 (2.24-13.40)
Recent CD4+ cell count (vs. >350)			
<200	1.51 (1.01-2.27)	2.06 (1.36-3.13)	1.98 (1.07-3.69)
200-350	1.31 (0.94-1.80)	1.46 (1.03-2.05)	1.27 (0.74-2.18)
% time CD4+ cell count <200 (vs. <40%)			
40-80%	0.70 (0.44-1.11)	0.65 (0.41-1.05)	0.70 (0.35-1.42)
>80%	1.14 (0.69-1.90)	1.07 (0.64-1.81)	1.25 (0.59-2.63)
HCV treatment (vs. no treatment)			
Treatment w/o SVR	0.87 (0.59-1.28)	0.74 (0.49-1.11)	0.86 (0.47-1.57)
Treatment w/ SVR	0.92 (0.47-1.84)	0.71 (0.34-1.46)	0.47 (0.11-1.94)
HCV Genotype (vs. Type 2,3)			
Type 1,4	1.71 (1.00-2.92)	1.63 (0.94-2.83)	2.27 (0.96-5.38)
Not Done	1.70 (0.96-3.03)	2.18 (1.20-3.96)	2.42 (0.95-6.13)

*Full models are presented for each analysis